Study of an experimental drug for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 1 trial tests VVD-130037, a new experimental medicine, to see if it is safe and tolerable in people with advanced (metastatic or unresectable) solid cancers. If you have already tried standard treatments and your body can handle study medication, you may be eligible—especially for certain lung, head and neck, or esophageal cancer types with specific genetic changes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed metastatic or unresectable solid tumor (cancer found on biopsy or scan tissue sample).
- Your cancer can be measured on imaging (it must meet specific measurement rules set by the study).
- You have tried and your cancer progressed after all standard treatments for advanced disease.
- Your energy/strength level is good enough (ECOG 0–1).
- Your organs and bone marrow work well enough for safe treatment (lab results must meet study targets).
- You do not have key reasons to be excluded, including certain genetic mutation types and serious heart or brain-related issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new oral medication, VVD-133214, for people with advanced solid tumors that have a specific genetic feature called MSI-high or dMMR. The study will see if the drug is safe and effective when given alone or with other drugs like bevacizumab or pembrolizumab.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This trial tests an experimental drug called VBC108 in people with advanced solid tumors that have not responded to other treatments. The study aims to see if the drug is safe and effective.
This trial tests two new injectable drugs for advanced solid tumors, especially kidney, head and neck, cervical, and ovarian cancers. The goal is to see if the combination is safe and if it can shrink tumors.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests two experimental drugs given together to treat advanced solid tumors that have not responded to previous treatments. The goal is to see if the combination helps shrink or control the cancer, and the study is for people who are otherwise in fairly good health.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.